<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Marvell Technology Group Ltd — News on 6ix</title>
<link>https://6ix.com/company/marvell-technology-group-ltd</link>
<description>Latest news and press releases for Marvell Technology Group Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/marvell-technology-group-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68359d5a78dffbe2df1078cd.webp</url>
<title>Marvell Technology Group Ltd</title>
<link>https://6ix.com/company/marvell-technology-group-ltd</link>
</image>
<item>
<title>Marvell Announces Acquisition of Polariton Technologies, Advancing Optical Performance Scaling to 3.2T and Beyond</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvell-announces-acquisition-of-polariton-technologies-advancing-optical-performance-scaling-to-32t-and-beyond-10</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvell-announces-acquisition-of-polariton-technologies-advancing-optical-performance-scaling-to-32t-and-beyond-10</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>Adds Plasmonics-based Modulation Technology and a Team with Deep Silicon Photonics Expertise to Advance Marvell’s Optical Roadmap SANTA CLARA,</description>
</item>
<item>
<title>Marvel Biosciences Announces Closing of Convertible Debenture Offering</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-announces-closing-of-convertible-debenture-offering-1</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-announces-closing-of-convertible-debenture-offering-1</guid>
<pubDate>Fri, 17 Apr 2026 20:30:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - April 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today that it has completed the closing of the previously announced non-brokered private placement of unsecured convertible debentures ("Debentures") for gross proceeds of $500,000 (the "Offering"), subject to final approval of the TSX Venture Exchange.The Debentures bear interest at the rate of twelve percent (12%) per annum, payable annually and mature on December..</description>
</item>
<item>
<title>Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-identifies-liquid-formulations-for-neurodevelopmental-disorders-1</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-identifies-liquid-formulations-for-neurodevelopmental-disorders-1</guid>
<pubDate>Thu, 16 Apr 2026 11:00:00 GMT</pubDate>
<description>CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204. This work was supported by a National Research Council of Canada Indust</description>
</item>
<item>
<title>Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-announces-an-amendment-to-the-conversion-price-for-marvels-proposed-convertible-debenture-offering-1</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-announces-an-amendment-to-the-conversion-price-for-marvels-proposed-convertible-debenture-offering-1</guid>
<pubDate>Mon, 13 Apr 2026 21:31:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") Further to the Company's press release of April 8, 2026, announcing its intention to complete a non-brokered private placement offering of unsecured convertible debentures ("Debentures") in the principal amount of up to $500,000 (the "Offering"), Marvel wishes to announce that it has amended the conversation price for the Debentures, which are convertible at the holder's option</description>
</item>
<item>
<title>Marvel Biosciences Announces Proposed Convertible Debenture Offering</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-announces-proposed-convertible-debenture-offering-1</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-announces-proposed-convertible-debenture-offering-1</guid>
<pubDate>Wed, 08 Apr 2026 20:30:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - April 8, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures ("Debentures") in the principal amount of up to $500,000 (the "Offering"), subject to final approval of the TSX Venture Exchange.The Debentures will bear interest at the rate of twelve percent (12%) per annum, payable annually and mature on December 31, 2027...</description>
</item>
<item>
<title>Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-secures-financial-and-strategic-investment-with-5-horizon-ventures-1</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-secures-financial-and-strategic-investment-with-5-horizon-ventures-1</guid>
<pubDate>Tue, 07 Apr 2026 11:30:00 GMT</pubDate>
<description>CALGARY, Alberta, April 07, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions, today announces that is has secured financial and strategic support from 5 Horizons Ventures for the Company’s upcoming Phase I clinical trial of its lead drug candidate, MB-204. 5 Hori</description>
</item>
<item>
<title>NVIDIA AI Ecosystem Expands as Marvell Joins Forces Through NVLink Fusion</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/nvidia-ai-ecosystem-expands-as-marvell-joins-forces-through-nvlink-fusion-1</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/nvidia-ai-ecosystem-expands-as-marvell-joins-forces-through-nvlink-fusion-1</guid>
<pubDate>Tue, 31 Mar 2026 12:00:00 GMT</pubDate>
<description>Collaboration Delivers Greater Choice and Flexibility for Customers and Fully Compatible With NVIDIA AI InfrastructureSANTA CLARA, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- NVIDIA and Marvell Technology, Inc. (NASDAQ: MRVL) today announced a strategic partnership to connect Marvell to the NVIDIA AI factory and AI-RAN ecosystem through NVIDIA NVLink Fusion™, offering customers building on NVIDIA architectures greater choice and flexibility in developing next-generation infrastructure. The compan</description>
</item>
<item>
<title>Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-secures-alberta-innovates-funding-to-support-the-phase-i-testing-of-mb-204-1</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-secures-alberta-innovates-funding-to-support-the-phase-i-testing-of-mb-204-1</guid>
<pubDate>Mon, 30 Mar 2026 11:30:00 GMT</pubDate>
<description>CALGARY, Alberta, March 30, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced it has secured non-dilutive funding from the Alberta Innovates CarE (AICE) market access program to support the Phase I testing of its lead compound, MB-204. The $600,000</description>
</item>
<item>
<title>Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-selects-novotech-as-cro-for-its-phase-i-clinical-trial-of-mb-204-1</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-selects-novotech-as-cro-for-its-phase-i-clinical-trial-of-mb-204-1</guid>
<pubDate>Wed, 25 Mar 2026 11:30:00 GMT</pubDate>
<description>CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions is pleased to announce that it has selected Novotech as the contract research organization (“CRO”) for the Company’s upcoming Phase I for its lead drug candidate MB-204. Novotech is an i</description>
</item>
<item>
<title>Matt Murphy, Marvell Chairman and CEO, to Keynote at COMPUTEX 2026</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/matt-murphy-marvell-chairman-and-ceo-to-keynote-at-computex-2026</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/matt-murphy-marvell-chairman-and-ceo-to-keynote-at-computex-2026</guid>
<pubDate>Thu, 19 Mar 2026 05:20:00 GMT</pubDate>
<description>One of COMPUTEX's organizers—TAITRA (Taiwan External Trade Development Council) today announced that Matt Murphy, Chairman and CEO of Marvell Technology, will deliver a keynote at COMPUTEX 2026. The keynote is scheduled for June 2nd at 10:30 a.m. (GMT+8) at the Taipei Nangang Exhibition Center Hall 2, 7F.</description>
</item>
<item>
<title>Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-receives-notice-of-allowance-for-us-patent-application-covering-composition-of-matter-for-its-lead-therapeutic-candidate-mb-204-1</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvel-biosciences-receives-notice-of-allowance-for-us-patent-application-covering-composition-of-matter-for-its-lead-therapeutic-candidate-mb-204-1</guid>
<pubDate>Wed, 18 Mar 2026 11:00:00 GMT</pubDate>
<description>Calgary, Alberta--(Newsfile Corp. - March 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce that the US Patent Office has issued Patent No. 12,570,656 B2 for MB-204 granting broad composition of matter and methods of use claims titled "Purine Compounds</description>
</item>
<item>
<title>Marvell Launches Next-generation CXL Switch, Enabling Memory Pooling to Break Through the AI "Memory Wall"</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvell-launches-next-generation-cxl-switch-enabling-memory-pooling-to-break-through-the-ai-memory-wall</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvell-launches-next-generation-cxl-switch-enabling-memory-pooling-to-break-through-the-ai-memory-wall</guid>
<pubDate>Tue, 17 Mar 2026 13:02:00 GMT</pubDate>
<description>LOS ANGELES, March 17, 2026--OFC 2026 – Marvell Technology, Inc. (NASDAQ: MRVL), a leader in data infrastructure semiconductor solutions, today announced Marvell® Structera™ S 30260―a new 260-lane CXL switch device that enables rack-level memory pooling. Working in concert with Marvell Structera A near-memory accelerators, Structera X memory-expansion controllers and Alaska® P PCIe/CXL retimers, the new switch allows data center operators to further increase memory bandwidth and capacity by prov</description>
</item>
<item>
<title>Marvell Launches Next-generation CXL Switch, Enabling Memory Pooling to Break Through the AI “Memory Wall”</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvell-launches-next-generation-cxl-switch-enabling-memory-pooling-to-break-through-the-ai-memory-wall-1</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvell-launches-next-generation-cxl-switch-enabling-memory-pooling-to-break-through-the-ai-memory-wall-1</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Marvell Structera S Pooling Capability Offers Higher Memory Utilization, Improved Data Flow Efficiency and AI Application Performance, and Greater</description>
</item>
<item>
<title>Marvell Launches Industry’s First 260-lane PCIe 6.0 Switch for AI Data Center Scale-up Infrastructure</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvell-launches-industrys-first-260-lane-pcie-60-switch-for-ai-data-center-scale-up-infrastructure</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvell-launches-industrys-first-260-lane-pcie-60-switch-for-ai-data-center-scale-up-infrastructure</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Marvell Structera S Delivers 2x the Lane Density of Competitive Offerings, Expanding Marvell End-to-End PCIe Product Portfolio and Redefining PCIe Scale-up</description>
</item>
<item>
<title>Marvell and Lumentum to Demonstrate Optical Circuit Switching for Next-generation AI Scale-up Infrastructure</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvell-and-lumentum-to-demonstrate-optical-circuit-switching-for-next-generation-ai-scale-up-infrastructure-2</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvell-and-lumentum-to-demonstrate-optical-circuit-switching-for-next-generation-ai-scale-up-infrastructure-2</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>Live OFC Demonstration to Showcase Low Latency, Flexible, Energy-efficient Network Fabrics for Hyperscaler AI Data Centers LOS ANGELES--(BUSINESS WIRE)-- OFC</description>
</item>
<item>
<title>Marvell to Showcase Industry-leading, End-to-End Connectivity Solutions for AI Data Center Infrastructure at OFC 2026</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvell-to-showcase-industry-leading-end-to-end-connectivity-solutions-for-ai-data-center-infrastructure-at-ofc-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvell-to-showcase-industry-leading-end-to-end-connectivity-solutions-for-ai-data-center-infrastructure-at-ofc-2026-5</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Over 100 Marvell and Ecosystem Partner Technology Demos and High-profile Executive Presentations Underscore Marvell Position as a Driving Force in Next-gen</description>
</item>
<item>
<title>Marvell Ushers In the 1.6T Era with Expanded Optical DSP Platform Portfolio, Redefining AI Data Center End-to-End Connectivity</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvell-ushers-in-the-16t-era-with-expanded-optical-dsp-platform-portfolio-redefining-ai-data-center-end-to-end-connectivity-3</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvell-ushers-in-the-16t-era-with-expanded-optical-dsp-platform-portfolio-redefining-ai-data-center-end-to-end-connectivity-3</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Multi-generational, Industry-leading DSPs, Advanced SerDes and Industry’s Broadest End-to-End Connectivity Portfolio Position Marvell as the Driving Force in</description>
</item>
<item>
<title>Marvell and Mojo Vision Collaborate to Develop Next-generation, High-density Micro-LED Connectivity Solutions</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvell-and-mojo-vision-collaborate-to-develop-next-generation-high-density-micro-led-connectivity-solutions-7</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvell-and-mojo-vision-collaborate-to-develop-next-generation-high-density-micro-led-connectivity-solutions-7</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Short-reach Optical Interconnects Deliver Industry-leading Bandwidth Density, Power Efficiency and Reliability to Power Broad Range of AI Data Center</description>
</item>
<item>
<title>Marvell Technology, Inc. Reports Fourth Quarter and Fiscal Year 2026 Financial Results</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvell-technology-inc-reports-fourth-quarter-and-fiscal-year-2026-financial-results-71</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvell-technology-inc-reports-fourth-quarter-and-fiscal-year-2026-financial-results-71</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Q4 Net Revenue: $2.219 billion, a new record, grew by 22% year-on-year Q4 Gross Margin: 51.7% GAAP gross margin; 59.0% non-GAAP gross margin Q4 Diluted</description>
</item>
<item>
<title>Marvell Extends ZR/ZR+ Leadership with Industry-first 1.6T ZR/ZR+ Pluggable and 2nm Coherent DSPs for Secure AI Scale-across Interconnects</title>
<link>https://6ix.com/company/marvell-technology-group-ltd/news/marvell-extends-zrzr-leadership-with-industry-first-16t-zrzr-pluggable-and-2nm-coherent-dsps-for-secure-ai-scale-across-interconnects-30</link>
<guid isPermaLink="true">https://6ix.com/company/marvell-technology-group-ltd/news/marvell-extends-zrzr-leadership-with-industry-first-16t-zrzr-pluggable-and-2nm-coherent-dsps-for-secure-ai-scale-across-interconnects-30</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Multi-generational ZR/ZR+ Technology with Integrated MACsec and High-volume Manufacturing Capacity to Meet Surging AI Data Center Demand SANTA CLARA,</description>
</item>
</channel>
</rss>